Welcome to our dedicated page for Charles River Laboratories International news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles River Laboratories International stock.
Founded in 1947, Charles River Laboratories International, Inc. (symbol: CRL) is a global leader in providing essential products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions. The company's mission is to accelerate research and drug development efforts, significantly contributing to the healthcare industry.
Charles River operates through three main segments:
- Research Models & Services: This segment is renowned for being the leading provider of laboratory animal models. Charles River breeds and supplies animals with specific genetic traits for preclinical studies worldwide, supporting the critical early stages of drug discovery.
- Discovery & Safety Assessment: This segment offers a comprehensive range of services necessary for the early development of new drugs. From discovery services to safety assessments, Charles River helps clients navigate the complex process of taking a drug from concept to early-stage development.
- Manufacturing Support: This includes microbial solutions for in vitro testing, biologics testing services, and avian vaccine services. These services are integral to ensuring the safe manufacture and quality control of new therapies.
The company's workforce is dedicated to providing clients with the expertise and services they need to improve and expedite the discovery and development of new therapies. Charles River's collaborative approach and commitment to excellence have established it as a trusted partner in the life sciences industry.
Charles River continues to innovate and expand its services, making significant strides in the fields of drug discovery, biotechnology, and pharmaceuticals. With a strong financial footing and strategic partnerships, the company is well-positioned to support the future of healthcare advancements globally.
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) invests $200M in alternative testing methods and achieves 92% renewable energy usage worldwide, showcasing significant ESG progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) collaborates with National University of Singapore’s Yong Loo Lin School of Medicine to provide phase-appropriate plasmid DNA for cancer therapy. This partnership aims to support the development of engineered stem cells for cancer treatment, leveraging Charles River's expertise in HQ and GMP-compliant plasmid DNA manufacturing. The collaboration will utilize Charles River’s eXpDNA™ platform to enhance NUS Medicine's research capabilities in stem cell biology and therapy, offering a complete solution from concept to cure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
-
Rhea-AI Summary
Charles River Laboratories and Navega Therapeutics announce an AAV9 production program agreement to develop a non-opioid gene therapy, NT-Z001, for chronic pain disorders. Navega's AI-enabled zinc-finger epigenome regulation platform targets rare diseases like small fiber neuropathy and primary erythromelalgia, addressing a gain-of-function mutation in the Nav 1.7 gene. With over 17 million Americans suffering from chronic pain, this therapy shows promise for various pain indications. Charles River's CGT Accelerator Program supports Navega's efforts by providing CDMO solutions and advisory services to expedite clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) will present at the Barclays 26th Annual Global Healthcare Conference, discussing strategic focus, business developments, and recent trends. The webcast will be available on their Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
-
Rhea-AI Summary
Wheeler Bio, Inc. partners with Charles River Laboratories International, Inc. to offer Portable CMC® platform, aiming to streamline therapeutic discovery and accelerate IND submission timelines. The collaboration combines expertise in antibody discovery, safety, and analytics to simplify the development process and provide a comprehensive concept-to-commercial offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) announces a strategic agreement with Wheeler Bio, Inc. to provide early-stage biotech companies with access to Wheeler's Portable CMC® platform, accelerating therapeutic discovery timelines. This collaboration aims to streamline preclinical to clinical manufacturing processes, reducing vendor complexities and integrating CMC development early in discovery. Wheeler's mission is to solve translational challenges in advancing from discovery to CMC development and early-clinical trial material supply.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
News
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has partnered with Pluristyx Inc. to expand its stem cell research tools, including high-quality embryonic stem cells and induced pluripotent stem cells. The collaboration aims to accelerate therapeutic development by providing researchers with advanced cell lines and technologies for new therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) reports fourth-quarter revenue of $1.01 billion, full-year revenue of $4.13 billion, with GAAP earnings per share of $3.62 and non-GAAP earnings per share of $2.46. The company provided 2024 guidance, anticipating a cautious biopharmaceutical demand environment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.3%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has launched the Endosafe® Trillium™ rCR cartridge offering, an animal-free testing solution that enhances testing efficiency and accelerates manufacturing timelines. This innovation builds upon the company's flagship Endosafe® cartridge technology and their recombinant cascade reagent (rCR) to bolster commitments to sustainability and animal welfare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) has appointed Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer of Novartis US, to its Board of Directors. With 25 years of experience in the pharmaceutical industry, Ms. Kemps-Polanco will bring valuable insights and knowledge to Charles River's Board. Her extensive experience in leading commercial organizations and her commitment to improving patient access and health outcomes will greatly benefit Charles River's growth strategy. As a member of the Board, she will serve on the Compensation and Strategic Planning and Capital Allocation Committees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
FAQ
What is the current stock price of Charles River Laboratories International (CRL)?
The current stock price of Charles River Laboratories International (CRL) is $187.9 as of November 20, 2024.
What is the market cap of Charles River Laboratories International (CRL)?
The market cap of Charles River Laboratories International (CRL) is approximately 10.6B.
What services does Charles River Laboratories provide?
Charles River provides research models, discovery and safety assessment services, and manufacturing support, including microbial solutions, biologics testing, and avian vaccine services.
When was Charles River Laboratories founded?
Charles River Laboratories was founded in 1947.
Who are Charles River Laboratories' primary clients?
The company's primary clients are pharmaceutical and biotechnology companies, government agencies, and leading academic institutions.
What is Charles River Laboratories' mission?
Charles River's mission is to accelerate research and drug development efforts globally.
What is included in the Research Models & Services segment?
This segment includes providing laboratory animal models with specific genetic traits for preclinical studies.
What does the Discovery & Safety Assessment segment offer?
This segment offers services for the early development of new drugs, including discovery services and safety assessments.
What are some of the services provided under Manufacturing Support?
Manufacturing Support includes microbial solutions for in vitro testing, biologics testing services, and avian vaccine services.
How does Charles River contribute to the healthcare industry?
Charles River helps expedite the discovery and development of new therapies, aiding in research and the safe manufacture of new drugs.
What makes Charles River Laboratories a trusted partner in the life sciences industry?
The company's commitment to excellence, innovative approach, and comprehensive service offerings make it a trusted partner.
What is the ticker symbol for Charles River Laboratories International, Inc.?
The ticker symbol for Charles River Laboratories International, Inc. is CRL.
Charles River Laboratories International, Inc.
NYSE:CRL
CRL Rankings
CRL Stock Data
10.63B
50.64M
0.92%
103.97%
3.62%
Diagnostics & Research
Services-commercial Physical & Biological Research
United States of America
WILMINGTON